Expression of tyrosine kinase receptors in malignant midgut carcinoid tumors

Neuroendocrinology

Volumn 84, Issue 1, 2006, Pages 42-48

  Welin, Staffan ^a,b   Fjällskog, Marie Louise ^a   Saras, Jan ^a   Eriksson, Barbro ^a   Janson, Eva T ^a  

^a UPPSALA UNIVERSITY   (Sweden)

^b UPPSALA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Carcinoid tumor; Immunohistochemistry; Trastuzumab, treatment; Tyrosine kinase receptors

Indexed keywords

ANTICOAGULANT AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR; IMATINIB; MONOCLONAL ANTIBODY; OCTREOTATE LU 177; PENTETREOTIDE IN 111; PLATELET DERIVED GROWTH FACTOR ALPHA RECEPTOR; PLATELET DERIVED GROWTH FACTOR BETA RECEPTOR; POLYCLONAL ANTIBODY; PROTEIN TYROSINE KINASE INHIBITOR; PROTON PUMP INHIBITOR; SOMATOSTATIN DERIVATIVE; STEM CELL FACTOR RECEPTOR; TYROSINE KINASE RECEPTOR;

ADULT; AGED; ARTICLE; BLEEDING; BON1 CELL; CELL CULTURE; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; MALE; MIDGUT; NEUROENDOCRINE TUMOR; PRIORITY JOURNAL; PROTEIN EXPRESSION; STAINING; STOMACH CARCINOID; TUMOR CELL; TUMOR GROWTH; VEIN THROMBOSIS;

ADULT; AGED; ANTIBODIES, MONOCLONAL; CARCINOID TUMOR; FEMALE; GASTROINTESTINAL NEOPLASMS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; MIDDLE AGED; PROTO-ONCOGENE PROTEINS C-KIT; RECEPTOR PROTEIN-TYROSINE KINASES; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, PLATELET-DERIVED GROWTH FACTOR ALPHA; RECEPTOR, PLATELET-DERIVED GROWTH FACTOR BETA;

EID: 33845734120     PISSN: 00283835     EISSN: None     Source Type: Journal    
DOI: 10.1159/000096294     Document Type: Article

References (23)

1. Druker BJ, Talpaz M, Resta DJ, Peng B, Buchdunger E, Ford JM, Lydon NB, Kantarjian H, Capdeville R, Ohno-Jones S, Sawyers CL: Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 2001;344:1031-1037.
2. Dagher R, Cohen M, Williams G, Rothmann M, Gobburu J, Robbie G, Rahman A, Chen G, Staten A, Griebel D, Pazdur R: Approval summary: imatinib mesylate in the treatment of metastatic and/or unresectable malignant gastrointestinal stromal tumors. Clin Cancer Res 2002;8:3034-3038.
3. Apperley JF, Gardembas M, Melo JV, Russel-Jones R, Bain BJ, Baxter J, Chase A, Chessells JM, Colombat M, Dearden CE, Dimitrijevic S, Mahon FX, Marin D, Nikolova Z, Olavarria E, Silberman S, Schultheis B, Cross NCP, Goldman JM: Response to Imatinib mesylate in patients with chronic myeloproliferative diseases with rearrangements of the platelet-derived growth factor receptor beta. N Engl J Med 2002;347:481-487.
4. Grünwald V, Hidalgo M: Developing inhibitors of the epidermal growth factor receptor for cancer treatment. J Natl Cancer Inst 2003;95:851-867.
5. Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, Fleming T, Weiermann W, Wolter J, Pegram M, Baselga J, Norton L: Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpress HER2. N Engl J Med 2001;344:783-792.
6. Robert F, Ezekiel MP, Spencer SA, Meredith RF, Bonner JA, Khazaeli MB, Saleh MN, Carey D, LoBuglio AF, Wheeler RH, Cooper MR, Waksal HW: Phase 1 study of anti-epidermal growth factor receptor antibody cetuximab in combination with radiation therapy in patients with advanced head and neck cancer. J Clin Oncol 2001;19:3234-3243.
7. Cunningham D, Humblet Y, Siena S, Khayat D, Bleiberg H, Santoro A, Bets D, Mueser M, Harstrick A, Verslype C, Chau I, Van Cutsem E: Cetuximab monotherapy and cetuximab plus irinotecan in iranotecan-refractory metastatic colorectal cancer. N Engl J Med 2004;351;4:337-345.
8. Philip PA, Mahoney MR, Allmer C, Thomas J, Pitot HC, Kim G, Donehower RC, Fitch T, Picus J, Erlichman C: Phase II study of erlotinib (OSI-774) in patients with advanced hepatocellular cancer. J Clin Oncol 2005;23:6657-6663.
9. Fukuoka M, Yano S, Giaccone G, Tamura T, Nakagawa K, Douillard JY, Nishiwaki Y, Vansteenkiste J, Kudoh S, Rischin D, Eek R, Horai T, Noda K, Takata I, Smit E, Averbu Takata I, Smit E, Averbuch S, Macleod A, Feyereislova A, Dong RP, Baselga J: Multiinstitutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial). J Clin Oncol 2003;21:2237-2246.
10. Cohen EEW, Rosen F, Stadler WM, Recant W, Stenson K, Huo D, Vokes EE: Phase II trial of ZD1839 in recurrent or metastatic squamous cell carcinoma of the head and neck. J Clin Oncol 2003;21:1980-1987.
11. Höpfner M, Sutter AP, Gerst B, Zeitz M, Scherübl H: A novel approach in the treatment of neuroendocrine gastrointestinal tumours. Targeting the epidermal growth factor receptor by gefitinib (ZD 1839). Br J Cancer 2003;89:1766-1775.
12. Fjallskog ML, Lejonklou MH, Oberg KE, Eriksson BK, Janson ET: Expression of molecular targets for tyrosine kinase receptor antagonists in malignant endocrine pancreatic tumors. Clin Cancer Res 2003;9:1469-1473.
13. Mellstroom K, Hoglund AS, Nister M, Heldin CH, Westermark B, Lindberg U: The effect of platelet-derived growth factor on morphology and motility of human glial cells. J Muscle Res Cell Motil 1983;4:589-609.
14. Chaudhry A, Papanicolaou V, Öberg K, Heldin CH, Funa K: Expression of platelet-derived growth factor and its receptor in neuroendocrine tumors of the digestive system. Cancer Res 1992;52:1006-1012.
15. Funa K, Papanicolaou V, Juhlin C, Rastad J, Åkerström G, Heldin CH, Öberg K: Expression of platelet-derived growth factor β-receptors on stromal tissue cells in human carcinoid tumors. Cancer Res 1990;50:748-753.
16. Nilsson O, Wängberg B, Kölby L, Schultz GS, Ahlman H: Expression of transforming growth factor-α and its receptor in human neuroendocrine tumours. Int J Cancer 1995;60:645-651.
17. Wulbrand U, Wied M, Zöfel P, Göke B, Arnold R, Fehmann HC: Growth factor receptor expression in human gastroenteropancreatic neuroendocrine tumours. Eur J Clin Invest 1998;28:1038-1049.
18. Papouchado B, Erickson LA, Rohlinger AL, Hobday TJ, Erlichman C, Ames MM, Lloyd RV: Epidermal growth factor receptor and activated epidermal growth factor receptor expression in gastrointestinal carcinoids and pancreatic endocrine carcinomas. Mod Pathol 2005;18:1329-1335.
19. Soulieres D, Senzer NN, Vokes EE, Hidalgo M, Agarwala SS, Siu LL: Multicenter phase II study of erloinib, an oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with recurrent or metastatic squamous cell cancer of the head and neck. J Clin Oncol 2004;22:77-85.
20. Paez JG, Jänne PA, Lee JC, Tracy S, Greulich H, Gabriel S, Herman P, Kaye FJ, Lindeman N, Boggon TJ, Naoki K, Sasaki H, Fujii Y, Eck MJ, Sellers WR, Johnson BE, Meyerson M: EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004;304:1497-1500.
21. Lynch T, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW, Harris PL, Haserlat SM, Supko JG, Haluska FG, Louis DN, Christiani DC, Settleman J, Haber DA: Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small cell lung cancer to gefitinib. N Engl J Med 2004;350:2129-2139.
22. Tsuchihashi Z, Hanna N, Jänne PA: Responsiveness to cetuximab without mutations in EGFR. N Engl J Med 2005;353:208-209.
23. Ogino S, Meyerhardt JA, Cantor M, Brahmandam M, Clark JW, Namgyal C, Kawasaki T, Kinsella K, Michelini AL, Enziger PE, Kulke MH, Ryan DP, Loda M, Fuchs CS: Molecular alterations in tumors and response to combination chemotherapy with gefitinib for advanced colorectal cancer. Clin Cancer Res 2005;11:6650-6656.